Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi

Medical Mycology

Volumn 36, Issue 6, 1998, Pages 433-436

  Marco, F ^a,b   Pfaller, M A ^a   Messer, S A ^a   Jones, R N ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Moulds; Triazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; TRIAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; FUSARIUM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOULD; NONHUMAN; RHIZOPUS; YEAST;

ASPERGILLUS; FUNGI; FUSARIUM; RHIZOPUS;

EID: 33746467018     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-280x.1998.00170.x     Document Type: Article

References (12)

1. Barry AL, Brown SD. In vitro studies of two antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996; 40: 1948-9.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
3. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998; 42: 161-3.
4. Patterson BE, Coates PE. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In: Program and Abstracts of the Thirtysixth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco CA, Abstract F78. Washington DC: American Society for Microbiology, 1995: 126.
5. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41: 575-7.
6. Dupont B, Denning D, Lode H, Yonren S, Troke PF, Sarantis N. UK-109,496, a novel, wide-spectrum triazole derivaative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. In: Program and Abstracts of the Thirtysixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, Abstract F81. Washington DC: American Society for Microbiology, 1995: 127.
7. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 696-8.
8. Martin MV, Yatcs J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41: 13-16.
9. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. Approved Standard M27-A. Wayne, PA: NCCLS, 1997.
10. Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35: 139-43.
11. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper Jr CR, Rinaldi MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997; 41: 1832-4.
12. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997; 41: 841-3.